Celldex Therapeutics
Price & Volume
Stats
See moreOpen | $26.23 |
Previous Close | $26.14 |
Day Range | $25.79-$26.48 |
52W Range | $14.40-$34.50 |
Market Cap | $1.7B |
Shares Short | 6M |
Financials
See moreRevenue (12 Mos) | $5.7M |
Revenue Growth (YoY) | -70.8% |
Gross Profit (12 Mos) | -$193.2M |
Diluted EPS | -$3.01 |
News
See moreYahoo Finance • 13 days ago
Celldex Presents Data Demonstrating Barzolvolimab Improves Chronic Spontaneous Urticaria Independent of Baseline Immunoglobulin E levels in Phase 2 Study at EADV Congress 2025
Yahoo Finance • 21 days ago
Celldex to Present at Morgan Stanley 23rd Annual Global Healthcare Conference
Yahoo Finance • last month
Chronic Inducible Urticaria (CIndU) Market Research Report 2025-2035 | Competitive Analysis of AstraZeneca, Celldex Therapeutics, J&J, Merck, Novartis, Pfizer, Regeneron Pharma, Sanofi, Sun Pharma
Yahoo Finance • last month
Celldex stock falls as barzolvolimab fails in EoE despite Cantor's positive view
About
CEO | Mr. Anthony S. Marucci M.B.A. |
CFO | Mr. Sam Martin CPA |
Address | Perryville III Building, Hampton, NJ, United States, 08827 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 186 |
